TP53 mutation and survival in chronic lymphocytic leukemia

Area of Science:

• Hematology
• Oncology
• Molecular Biology

Background:

• Chronic lymphocytic leukemia (CLL) prognosis is influenced by various genetic markers.
• The specific impact of TP53 mutations on treatment outcomes in CLL requires further clarification.

Purpose of the Study:

• To determine the prognostic significance of TP53 mutations in chronic lymphocytic leukemia (CLL).
• To evaluate the role of TP53 mutations in treatment algorithms for CLL.

Main Methods:

• TP53 mutations (exons 2-11) were assessed using denaturing high-performance liquid chromatography.
• Data were collected from a randomized prospective trial (n=375) with a 52.8-month follow-up (German CLL Study Group CLL4 trial).
• Treatments compared were fludarabine (F) versus F + cyclophosphamide (FC).

Main Results:

• TP53 mutations were identified in 8.5% of CLL patients.
• Patients with TP53 mutations had significantly worse progression-free survival (PFS) and overall survival (OS) compared to those without.
• TP53 mutation was the strongest independent prognostic marker for PFS and OS, irrespective of 17p deletion status.

Conclusions:

• CLL with TP53 mutation is associated with a poor prognosis, even without 17p deletion, when treated with fludarabine-based chemotherapy.
• TP53 mutation analysis should be integrated into the pre-treatment evaluation of CLL patients.
• Alternative treatment strategies should be considered for patients with TP53 mutations.